Abstract 1579P
Background
The US Surveillance, Epidemiology, and End Result (SEER) data indicated an increasing incidence of early-onset GI tract cancers. According to published data, the treatment outcomes of young adults (YA) are comparable to the general population. We aimed to analyze the clinicopathological characteristics and overall survival (OS) of YA treated in a comprehensive cancer center.
Methods
Patients diagnosed with oesophagal (OC), oesophagogastric junction (OGJ), or gastric (GC) cancer between 2010 and 2022 were retrospectively identified from the Masaryk Memorial Cancer Institute database. Inclusion criteria were 1) age 18-50 years, 2) histology, and 3) treatment according to international recommendations.
Results
The consecutive patient cohort included 1725 patients, of which 162 met the inclusion criteria, representing approximately 10% of YA patients from the Czech Republic. In 63% of cases, the patients were men, significantly older than women (84% vs 65% in the age group 40-49 years, p=0.005). In women, tumors were more often located in the stomach (78% vs 53%, p=0.001) and primary metastatic (67% vs 50%, p=0.039). Six patients had localized disease (stage I), 36 (16 OC/OGJ, 20 GC) underwent radical resection, 31 (15 OC/OGJ, 16 GC) were unresectable, and 86 metastatic (25 OC/OGJ, 61 GC). With a median follow-up of 67 months, 131 (81%) deaths were recorded. Radically resected patients achieved a median OS of 54 mo with a 5-year OS of 42%, whereas the median OS for the unresectable and metastatic disease was 11 mo, and 8.6 mo, respectively.
Conclusions
In our YA cohort, men were older, while women were more likely to have metastatic gastric cancer. OS for the locally advanced disease was comparable to published studies observing the general population but noticeably shorter for metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22
1644P - The mutation landscape and evolution pattern of liver or peritoneal metastasis in pancreatic cancer
Presenter: Guoliang Yao
Session: Poster session 22